Safety Assessment of Inactivated Whole Virion Booster Vaccine against the SARS-CoV-2 Virus (BelCovidVac) in Immunized Study Subjects aged 18 to 60 Years (day 28)

Relevance. According to the World Health Organization (WHO), it is not yet possible to effectively stop the spread of new strains of coronavirus [1]. At the same time, most experts and analysts in the field of medicine publicly admit that at the moment vaccination is the most powerful weapon in the...

Full description

Saved in:

Bibliographic Details
Main Authors:	I. O. Stoma, E. V. Voropaev, E. I. Mikhailova, D. M. Los, O. V. Osipkina, A. Yu. Braga, A. A. Kovalev, A. V. Molchanova, N. V. Trofimova, O. S. Pershenkova, B. S. Yaroshevich, M. N. Mirge
Format:	Article
Language:	Russian
Published:	Numikom LLC 2024-07-01
Series:	Эпидемиология и вакцинопрофилактика
Subjects:	covid-19 sars-cov-2 vaccination belcovidvac vaccine clinical trials safety adverse events
Online Access:	https://www.epidemvac.ru/jour/article/view/2019
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Safety Assessment of Inactivated Whole Virion Booster Vaccine against the SARS­-CoV-­2 Virus (BelCovidVac) in Immunized Study Subjects aged 18 to 60 Years (day 28)

Similar Items

Safety Assessment of Inactivated Whole Virion Booster Vaccine against the SARS-CoV-2 Virus (BelCovidVac) in Immunized Study Subjects aged 18 to 60 Years (day 28)